Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced the promotion of Thomas Englese to the position of chief commercial officer, effective immediately. Englese, who previously served as executive vice president of commercial operations since September 2024, will continue to lead sales, marketing, market access, and commercial operations for the company's key products, including TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg) for fibromyalgia in adults, as well as Zembrace® SymTouch® and Tosymra® for acute migraine.
The promotion comes at a pivotal time for Tonix as it works to broaden the launch of TONMYA, which was approved by the U.S. Food and Drug Administration as the first new treatment for fibromyalgia in more than 15 years. Seth Lederman, president and chief executive officer of Tonix, highlighted Englese's instrumental role in building the company's commercial organization and launching TONMYA, noting that his leadership will be key as the company continues to expand patient access and grow its prescriber base.
Englese expressed optimism about the company's trajectory, stating that the focus remains on increasing sales and broadening the TONMYA launch. His expanded role reflects Tonix's commitment to maximizing the commercial potential of its central nervous system (CNS) portfolio, which also includes treatments for acute migraine.
The announcement underscores Tonix's strategic shift toward commercialization, leveraging its integrated infrastructure to support both TONMYA and its migraine products. The company's CNS commercial infrastructure is designed to maximize the reach of its marketed products, while its pipeline remains active with several investigational candidates. Tonix is currently conducting Phase 2 clinical trials to evaluate TONMYA's potential in major depressive disorder and acute stress disorder, expanding the drug's possible applications beyond fibromyalgia.
Beyond TONMYA, Tonix is advancing a diverse pipeline that includes TNX-2900 for Prader-Willi syndrome, a rare disease, which is Phase 2 ready. In the immunology space, the company is developing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These candidates represent the company's broader focus on addressing high unmet medical needs in CNS and immunology.
The promotion of Englese is a clear signal of Tonix's dedication to building a robust commercial organization capable of driving growth in a competitive market. With TONMYA's recent launch and the ongoing expansion of its commercial team, the company is positioning itself to capitalize on the significant market opportunity presented by fibromyalgia, a condition that affects an estimated 10 million people in the United States.
Investors and industry observers will be watching closely to see how Englese's leadership influences TONMYA's market penetration and overall commercial performance. The company's ability to execute on its commercial strategy will be critical in the coming quarters as it seeks to establish a strong foothold in the CNS treatment landscape.
